Clinical Trial

Neoadjuvant PD-1 Inhibitor Combined With Cetuximab and Platinum in Resectable Locally Advanced Hypopharyngeal Carcinoma

Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated April 30, 2024 (before its estimated December 1, 2024 completion). Its status may not reflect the trial's current state.
Summary
The purpose of this clinical trial is to evaluate the efficacy and safety of immunotherapy combined with cetuximab and platinum neoadjuvant therapy in patients with resectable locally advanced hypopharyngeal cancer. Participants will receive three cycles of TPC neoadjuvant therapy (toripalimab+ cetuximab + platinum), radical surgery (laryngeal preservation surgery if possible), and sequential (chemo)radiotherapy treatment after surgery. This trial aims to answer the following questions: 1. pCR rate 2. MPR rate, ORR, LPR/DFS/OS rare at 1 and 2 years 3. Safety and quality of life
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2023-11-22.
Status change: Not Yet Recruiting → Recruiting 2024-04-28
Trial Details
NCT Number NCT06151743
Lead Sponsor Eye & ENT Hospital of Fudan University
Conditions Locally Advanced Hypopharyngeal Carcinoma
Enrollment 32 participants
Start Date 2024-01-18
Primary Completion 2024-12-01 (estimated)
Study Completion 2026-12-01 (estimated)
Updated on ClinicalTrials.gov 2024-04-30